Suchergebnisse - "Cahn, Avivit"

PubPharm (27)

1

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose : Post Hoc Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2023

von Pollack, R. | Raz, I. | Wiviott, S. | +13

2

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes : Post Hoc Analyses From the DECLARE-TIMI 58 Trial

enthalten in: Diabetes care | 2022

von Mosenzon, O. | Raz, I. | Wiviott, S. | +18

3

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes : Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2022

von Cahn, A. | Wiviott, S. | Mosenzon, O. | +12

CommentIn: Diabetes Care. 2022 Apr 1;45(4):766-768. - PMID 35349658

4

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

enthalten in: Diabetes care | 2021

von Berg, D. | Wiviott, S. | Scirica, B. | +15

5

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

enthalten in: Diabetes care | 2021

von Mosenzon, O. | Wiviott, S. | Heerspink, H. | +18

6

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort : Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2021

von Cahn, A. | Raz, I. | Leiter, L. | +12

7

Efficacy and Safety of Dapagliflozin in the Elderly : Analysis From the DECLARE-TIMI 58 Study

enthalten in: Diabetes care | 2020

von Cahn, A. | Mosenzon, O. | Wiviott, S. | +14

8

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease

enthalten in: Diabetes care | 2018

von Bergmark, B. | Bhatt, D. | Braunwald, E. | +8

9

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

enthalten in: Diabetes care | 2017

von Mosenzon, O. | Leibowitz, G. | Bhatt, D. | +12

10

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

enthalten in: Diabetes care | 2017

von Mosenzon, O. | Leibowitz, G. | Bhatt, D. | +12